Flavopiridol has been shown to potently inhibit CDK1 and 2 (cyclin-dependent kinases 1 and 2) and most recently it has been found that it also inhibits CDK9. The complex CDK9-cyclin T1 controls the elongation phase of ...

Flavopiridol has been shown to potently inhibit CDK1 and 2 (cyclin-dependent kinases 1 and 2) and most recently it has been found that it also inhibits CDK9. The complex CDK9-cyclin T1 controls the elongation phase of ...

Here is described a structural model for the binary complex CDK5-roscovitine. Roscovitine has been shown to potently inhibit cyclin-dependent kinases 1, 2 and 5 (CDK1, 2, and 5), and the structure of CDK2 complexed with ...

Roscovitine and flavopiridol have been shown to potently inhibit cyclin-dependent kinase 1 and 2 (CDK1 and 2). The structures of CDK2 complexed with roscovitine and deschoroflavopiridol have been reported, however no ...

Roscovitine and flavopiridol have been shown to potently inhibit cyclin-dependent kinase 1 and 2 (CDK1 and 2). The structures of CDK2 complexed with roscovitine and deschoroflavopiridol have been reported, however no ...

A set of different protein kinases have been involved in tau phosphorylations, including glycogen synthase kinase 3b (GSK3b), MARK kinase, MAP kinase, the cyclin-dependent kinase 5 (Cdk5) system and others. The latter ...

O presente trabalho descreve modelos moleculares para os complexos binários CDK9, CDK5 e CDK1 complexados com Flavopiridol e Roscovitina. Esses modelos estruturais indicam que os inibidores ligam-se fortemente ao sítio de ...

O presente trabalho descreve modelos moleculares para os complexos binários CDK9, CDK5 e CDK1 complexados com Flavopiridol e Roscovitina. Esses modelos estruturais indicam que os inibidores ligam-se fortemente ao sítio de ...

A number of natural and synthetic flavonoids have been assessed previously with regard to their effects on the activity of cyclin-dependent kinases (Cdk1 and -2) related to the inhibition of cell cycle progression. On the ...